ULTOMIRIS Drug Insight

“ULTOMIRIS Market Size, Forecast, and Drug Insight – 2032” report provides comprehensive insights about ULTOMIRIS for Atypical Hemolytic Uremic Syndrome in the 7MM. A detailed picture of the ULTOMIRIS for Atypical Hemolytic Uremic Syndrome in the 7MM, i.e., United States, EU4 (Germany, France, Italy, Spain) and the United Kingdom, and Japan, for the study period 2019–2032 is provided in this report along with a detailed description of the ULTOMIRIS for Atypical Hemolytic Uremic Syndrome. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the ULTOMIRIS market forecast, analysis for Atypical Hemolytic Uremic Syndrome in the 7MM, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about emerging therapies in Atypical Hemolytic Uremic Syndrome.

Drug Summary

ULTOMIRIS (ravulizumab) is a humanized monoclonal antibody (mAb) produced in Chinese hamster ovary cells (CHO). The first and only long-acting C5 inhibitor, administered every 8 weeks, works by inhibiting the C5 protein in the terminal complement cascade. It is a terminal complement inhibitor that specifically binds to the C5 protein of the terminal complement cascade and inhibits its breakdown.

ULTOMIRIS is indicated for treating adult patients with PNH and for the treatment of adults and pediatric patients 1 month of age and older with aHUS. The drug prevents the destruction of terminal complement-mediated red blood cells in patients with PNH. It is available as a sterile preservative-free solution in single-dose vials for intravenous administration. Each vial contains 300mg/30mL (10mg/mL) of ravulizumab-cwvz concentration at pH 7.

However, ULTOMIRIS increases the chance of getting serious and life-threatening meningococcal infections. Meningococcal infections may quickly become life-threatening and cause death if not recognized and treated early.

Mechanism of action

Ravulizumab-cwvz is a terminal complement inhibitor that specifically binds to the complement protein C5 with high affinity, thereby inhibiting its cleavage to C5a (the proinflammatory anaphylatoxin) and C5b (the initiating subunit of the terminal complement complex [C5b-9]) and preventing the generation of the terminal complement complex C5b9. ULTOMIRIS inhibits terminal complement-mediated intravascular hemolysis in patients with PNH and complement-mediated thrombotic microangiopathy (TMA) in patients with aHUS.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the ULTOMIRIS description, mechanism of action, dosage and administration, research and development activities in Atypical Hemolytic Uremic Syndrome.
• Elaborated details on ULTOMIRIS regulatory milestones and other development activities have been provided in this report.
• The report also highlights the ULTOMIRIS research and development activity in Atypical Hemolytic Uremic Syndrome details across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around ULTOMIRIS.
• The report contains forecasted sales of ULTOMIRIS for Atypical Hemolytic Uremic Syndrome till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Atypical Hemolytic Uremic Syndrome.
• The report also features the SWOT analysis with analyst views for ULTOMIRIS in Atypical Hemolytic Uremic Syndrome.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

ULTOMIRIS Analytical Perspective by DelveInsight

• In-depth ULTOMIRIS Market Assessment

This report provides a detailed market assessment of ULTOMIRIS in Atypical Hemolytic Uremic Syndrome in the 7MM, i.e., United States, EU4 (Germany, France, Italy, Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2022 to 2032.

• ULTOMIRIS Clinical Assessment

The report provides the clinical trials information of ULTOMIRIS for Atypical Hemolytic Uremic Syndrome covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights 

• In the coming years, the market scenario for Atypical Hemolytic Uremic Syndrome is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.  
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence ULTOMIRIS dominance.
• Other emerging products for Atypical Hemolytic Uremic Syndrome are expected to give tough market competition to ULTOMIRIS and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of ULTOMIRIS in Atypical Hemolytic Uremic Syndrome.
• Our in-depth analysis of the forecasted sales data of ULTOMIRIS from 2022 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the ULTOMIRIS in Atypical Hemolytic Uremic Syndrome.

Key Questions

• What is the product type, route of administration and mechanism of action of ULTOMIRIS?
• What is the clinical trial status of the study related to ULTOMIRIS in Atypical Hemolytic Uremic Syndrome and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the ULTOMIRIS development?
• What are the key designations that have been granted to ULTOMIRIS for Atypical Hemolytic Uremic Syndrome?
• What is the forecasted market scenario of ULTOMIRIS for Atypical Hemolytic Uremic Syndrome?
• What are the forecasted sales of ULTOMIRIS in the 7MM, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan? 
• What are the other emerging products available in Atypical Hemolytic Uremic Syndrome and how are they giving competition to ULTOMIRIS for Atypical Hemolytic Uremic Syndrome?
• Which are the late-stage emerging therapies under development for the treatment of Atypical Hemolytic Uremic Syndrome?"